Mammogen Featured in Forbes: Advancing the Future of Breast Cancer Detection

3 November 2026

November 3, 2026 | In the News | Forbes


Mammogen has been featured in Forbes in an article by Geri Stengel exploring the company's mission to transform breast cancer detection through innovative RNA-based blood testing.


The feature highlights Mammogen's co-founder and CEO, Elizabeth Cormier-May, and her vision for making earlier breast cancer detection more accessible, particularly for women with dense breast tissue.


At the center of the story is genTRU-breast™, Mammogen's investigational blood-based diagnostic designed to complement existing breast imaging and provide additional biological insights that may help inform clinical decisions.


The Forbes article also explores Mammogen's Series A financing of up to $30 million, its approach to affordability and patient access, and its ongoing commitment to prospective clinical validation.


A major focus is the KATELYN-ERIN clinical study, designed to enroll approximately 2,600 women to further evaluate the performance of genTRU-breast™.


As Mammogen continues advancing its technology toward clinical integration, the Forbes feature brings attention to an important challenge in women's health: improving access to meaningful information that can support earlier detection and more informed care.


Read the full Forbes feature: Mammogen Bets Women Will Pay $500 For A Breast Cancer Blood Test

Originally published by Forbes on November 3, 2026. Written by Geri Stengel. This summary was independently prepared by Mammogen. genTRU-breast™ is under clinical development, and prospective validation is ongoing.

Mammogen and MammoLink Partner to Advance Community-Based Breast Cancer Detection

27 October 2026
BioSpace | October 27, 2026 Mammogen has announced a clinical research partnership with MammoLink, a specialized women's health imaging provider, to expand community access to innovative breast cancer detection technologies. Through this collaboration, MammoLink will participate in Mammogen's KATELYN-ERIN clinical trial, a prospective study involving approximately 2,600 women. The partnership will leverage MammoLink's mobile 3D mammography network across Florida to evaluate Mammogen's genTRU-breast™ blood-based RNA assay alongside traditional breast imaging. The initiative represents an important step toward integrating molecular diagnostics with community-based breast care, with the goal of improving accessibility and supporting earlier breast cancer detection, particularly for women with dense breast tissue. Click Here to Read the Full Article on BioSpace

Mammogen CEO Featured on ASBN Discussing the Future of Breast Cancer Screening

23 October 2026
23 October 2026 America's Small Business Network (ASBN) | October 23, 2026 Mammogen CEO and Co-Founder Liz Cormier-May was featured on ASBN's The Female Founder Show, discussing the company's mission to advance breast cancer detection through innovative RNA-based blood testing. During the interview, Cormier-May highlighted the challenges women with dense breast tissue face with traditional mammography and explained how Mammogen's genTRU-breast™ blood-based assay is being developed to provide additional information that could support earlier detection. Cormier-May also shared the personal experiences behind Mammogen's founding, the challenges of advancing innovation in women's health, and her advice for aspiring female entrepreneurs. Click Here to Read the Full Article and Watch the Interview →

Mammogen Names National Cancer Screening Leader, Dr. Rebecca Kaltman, to Lead Pivotal genTRU-breast™ Study

20 October 2026
BioSpace | October 20, 2026 Mammogen announced the appointment of Rebecca D. Kaltman, M.D., Executive Director of the Inova Saville Cancer Screening and Prevention Center, as Principal Investigator for its KATELYN-ERIN clinical trial. The study will evaluate genTRU-breast™, Mammogen's RNA-powered blood-based assay being developed to support earlier breast cancer detection, particularly for women with dense breast tissue. Dr. Kaltman brings 20 years of experience in oncology, cancer prevention, and clinical research. Her leadership marks an important step as Mammogen advances its clinical validation efforts and explores how blood-based diagnostics can complement traditional breast imaging. Click Here to Read the Full Press Release →